DHHS → node
This is a follow-up to the message we sent on June 3, 2022. Under Section 90, we published a link to the Usual and Customary Rate (UCR), while we should have linked to the Section 90 fee schedule. Please see the corrected link below.
This message is a follow up to the August 13, 2021 message in which we announced the EVV “soft launch” period for providers of section 40 Home Health and section 43 Hospice services ahead of the January 1, 2023 federal implementation deadline.
This is a reminder that Targeted Case Managers supporting adults with Intellectual/Developmental Disabilities and/or Autism who are classified on MaineCare Benefits Manual Section 21 or 29 waivers must meet the following standards:
Good afternoon,
We are off to a good start on workers filling out the DHHS Telework Approval Form. To date, 708 forms have been submitted. Thanks to all involved in preparing and starting this process.
The Division of Policy posts all proposed and recently adopted rules on MaineCare’s Policy and Rules webpage. This website keeps the p
The Division of Policy posts all proposed and recently adopted rules on MaineCare’s Policy and Rules webpage. This website keeps the propo
Jun 6, 2022
While mental health challenges were all-too common before the pandemic, COVID-19 has exacerbated these conditions for many people in Maine and across the nation. Two in five American adults report experiencing anxiety and depression, and more than half of parents are concerned about their children’s mental well-being.
MaineCare is increasing reimbursement rates for certain services through a cost-of-living adjustment (COLA) as directed by Maine PL 2021, ch 635, Part A.
Effective May 17, 2022, the United States Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer pediatric COVID-19 vaccine booster for children ages five to eleven years old.
Effective May 17, 2022, the United States Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer pediatric COVID-19 vaccine booster for children ages five to eleven years old.